- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
From Benzinga
What This News Means for Merck
October 01, 2022
From Motley Fool
PhaseBio Might Have To Return Global Rights To Its Lead Program
September 28, 2022
From Benzinga
7 Large-Cap Stocks With Sustained Dividend Growth Potential
September 28, 2022
From InvestorPlace
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
September 27, 2022
From Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
September 27, 2022
From InvestorPlace
US Stock Futures Rise Ahead Of Economic Reports, Fed Speakers; Crude Oil Rises 1%
September 27, 2022
From Benzinga
Adding $100 to These 7 Stocks Would Be a Genius Move Right Now
September 27, 2022
From Motley Fool
Burberry Finance Chief Joins GSK As First Woman CFO
September 26, 2022
From Benzinga
European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders
September 25, 2022
From Benzinga
Should Growth Investors Buy This Little-Known Stock?
September 24, 2022
From Motley Fool
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
From Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
From Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
September 21, 2022
From Benzinga
Got $5,000? These 2 Growth Stocks Are Near Their 52-Week Lows
September 21, 2022
From Motley Fool
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
September 20, 2022
From Benzinga
Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead’s Veklury for severe disease
September 16, 2022
From MarketWatch
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
From Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
September 16, 2022
From Benzinga
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
September 14, 2022
From MarketWatch
From Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
September 13, 2022
From Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
From Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
From Benzinga
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
September 09, 2022
From Motley Fool
Got $5,000? These 2 Stocks Are No-Brainer Buys.
September 08, 2022
From Motley Fool
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
September 06, 2022
From Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
September 06, 2022
From Benzinga
Is This Blue Chip Dividend Stock a Buy?
September 05, 2022
From Motley Fool
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.